Nikkiso Clean Energy & Industrial Gases Group Announces Expansion of Service for Middle East and Northern Africa 31-01-2023, 05:49

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Brewing Success: Heineken® Renews Long-Standing Relationship with UEFA Champions League - Marking Over 30 Years Together 19-09-2023, 14:00